Is this title turning positive?
When a stock runs on rumors and the product never sells or is never licensed, this is what happens. It was the same with other products like Zika and others, products, rumors but revenues???, sales???. However, with the resurgence of Covid and its variants, it seems that THRM is coming back to the surface and that its product would be effective against variants such as Delta, this is where it starts to be interesting since the vaccine producers are not more advanced, apart from offering a 3rd dose (effective???) they have nothing to offer. This is where THRM has to come in and demonstrate its efficiency. This is where FIA has to impress us, no more being behind the others, sell more than hope, an effective product that will push THRM to new heights. The shareholders have been waiting for this moment for a long time. Will loyalty, despite the many frustrations, pay off?